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Background: A critical point in designing clinical trials comparing
chemotherapy with epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer
(NSCLC) is the expected benefit with standard chemotherapy in
presence of biological features indicative of TKI sensitivity. The aim
of this study was to assess whether EGFR and HER2 gene copy
number and Akt activation are associated with response to first-line
chemotherapy.
Methods: Tumor samples from 190 patients with NSCLC were
analyzed. EGFR and HER2 gene copy number were evaluated by
fluorescence in situ hybridization in 185 and 184 cases, respectively.
Akt activation was assessed by immunohistochemistry (n  176).
Additional biomarkers included EGFR DNA sequencing (n  65),
and EGFR immunohistochemistry (n  185).
Results: Response rate was not associated with EGFR, HER2, and
P-Akt status, irrespective of the method used for biomarker assess-
ment. Among patients with EGFR gene mutations, response to
chemotherapy was observed only in individuals with exon 19
deletion (response rate: 46.6% versus 0%, p  0.02). Among the
190 patients analyzed, 123 received a treatment with a TKI as
second- or third-line therapy. When assessed by fluorescence in
situ hybridization or DNA sequencing, EGFR-positive patients
seemed to be more sensitive to TKIs than to chemotherapy in
terms of response rate and time to progression, whereas in
EGFR-negative patients, response rate and time to progression
favored chemotherapy.
Conclusion: This study suggested that EGFR expression and gene
copy number, HER2 gene copy number, and P-Akt expression are
not associated with response to first-line chemotherapy in NSCLC.
Prospective phase III trials should compare standard chemotherapy
with a TKI in selected NSCLC.
Key Words: epidermal growth factor receptor, HER2, Akt, Che-
motherapy, Tyrosine kinase inhibitor, Non-small cell lung cancer.
(J Thorac Oncol. 2007;2: 423–429)
Non-small cell lung cancer (NSCLC) has been the leadingcause of cancer death in the world.1 Despite tangible
progresses have been made during the past decade, prognosis
of patients with this disease is still disappointing, and even
with newly developed chemotherapy strategies, the median
survival rarely exceeds 8 to 9 months.2–4 Combination of
cisplatin or carboplatin with third-generation agents such as
gemcitabine, paclitaxel, docetaxel, and vinorelbine represents
the standard of care for fit patients with advanced disease,3–5
whereas single-agent therapy with vinorelbine or gemcitabine
represents the standard approach for unfit or elderly NSCLC.6
Because further advances with chemotherapy are unlikely,
the key for improving outcomes for NSCLC patients turned
to targeted therapy. In particular, agents targeting the epider-
mal growth factor receptor (EGFR) have had a major impact
on the treatment of advanced NSCLC. Unfortunately, the
dominant clinical trial strategy for patients with NSCLC has
been to include a generic population of patients, with no
selection based on biological criteria and, most importantly,
with none or poor target assessment. Although recent clinical
trials in NSCLC have demonstrated survival improvement
without a defined biological endpoint,7,8 the hazard of con-
tinuing to perform clinical trials without any patient selection
carries the risk of administering the wrong drug to the wrong
patient and considering ineffective a drug that could dramat-
ically improve the outcome of some patients, even if those are
few in number.
Gefitinib (ZD 1839, Iressa; AstraZeneca) and erlotinib
(OSI 774, Tarceva; Genentech) are orally active, selective
EGFR tyrosine kinase inhibitors (EGFR-TKIs) that demon-
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strated antitumor activity in approximately 10% of unselected
NSCLC.9,10 During the past 2 years, molecular mechanisms
underlying TKI sensitivity have been identified. The main
biological events demonstrated to lead to TKI sensitivity are
the presence of specific EGFR gene mutations and increased
copy numbers of the EGFR gene.11–17 Additional studies
showed that other mechanisms are involved in TKI sensitiv-
ity, such as increased copy numbers of HER218 and activation
of the antiapoptotic protein Akt.19,20
The encouraging results in terms of response rate (RR),
time to disease progression (TTP), and survival observed in
recently completed phase II trials of TKIs in selected
NSCLC21–23 strongly support further phase III studies com-
paring a TKI with standard chemotherapy. A critical point in
designing such trials is the potential benefit from standard
chemotherapy in patients with biological features indicative
of TKI sensitivity. Large phase III randomized trials compar-
ing standard chemotherapy plus placebo or a TKI24–27
showed no overall benefit for patients receiving chemother-
apy plus TKI, raising concern that both modalities target the
same patient population. Although preclinical data showed
that EGFR or HER2 are implicated in the development of
cancer cells resistant to cytotoxic drugs,28 only few clinical
data are available in lung cancer and are confined to EGFR.29
In the retrospective study performed by Dziadziuszko et al.29
EGFR gene copy number or EGFR expression were not
associated with TTP or to survival of NSCLC patients treated
with chemotherapy. No clinical data exist on HER2, and the
role of Akt activation has been evaluated only in preclinical
models. In the study performed by Brogard et al.,30 Akt
resulted constitutively active in NSCLC cell lines and pro-
moted resistance to chemotherapy and radiation therapy. The
aim of this retrospective study was to evaluate whether
response to first-line chemotherapy is associated to EGFR
and HER2 gene copy numbers and to Akt activation.
METHODS
Patient Population
This retrospective study was conducted in a cohort of
190 NSCLC patients followed at the Bellaria-Maggiore Hos-
pital in Bologna (Italy) between January of 2001 and Decem-
ber of 2005. This cohort included 46 patients analyzed in
previously published studies.13,31 The primary endpoint was
response to chemotherapy according to EGFR and HER2
gene copy numbers and to Akt status, and secondary end-
points were response to chemotherapy according to presence
of EGFR mutations, TTP, and survival. Patients included into
the analysis were selected based on the following criteria:
histologically confirmed diagnosis of NSCLC; availability of
tumor tissue and full clinical data; presence of at least one
measurable lesion according to the Response Evaluation
Criteria In Solid Tumors32; metastatic or locally advanced
(stage III) NSCLC treated with standard first-line chemother-
apy and not treated with concomitant radiotherapy. Patients
were classified as never smoker (100 cigarettes per life-
time), former smoker (quit smoking 6 months before start-
ing chemotherapy therapy), or current smoker (quit smoking
6 months before starting chemotherapy or active smokers).
Written informed consent for study biomarker analyses was
obtained from each patient entering the study. The study was
conducted in accordance with ethical principles stated in the
most recent version of the Declaration of Helsinki or the
applicable guidelines on good clinical practice, whichever
represented the greater protection of the individual.
Tissue Preparation and Biomarker Analyses
Sections from paraffin-embedded tissue blocks contain-
ing representative malignant cells and obtained before any
cancer therapy was used for all analysis. Histopathological
classification was determined on hematoxylin-eosin–stained
sections based on the World Health Organization criteria.33
Gene copy number per cell was investigated by fluorescence
in situ hybridization (FISH) using the LSI EGFR Spectru-
mOrange/CEP 7 SpectrumGreen probe (Vysis, Abbott Mo-
lecular) and the PathVysion DNA probe Kit (Vysis, Abbott
Molecular), which includes the LSI HER-2 SpectrumOrange
and the CEP 17 SpectrumGreen probes. Assays and analyses
were performed as described elsewhere.13,16,18 Tumors were
classified as FISH positive when carrying four or more copies
of the gene in 40% or more of cells or gene amplification; and
FISH negative when carrying four or more copies of the gene
in less than 40% of cells.
Paraffin-embedded tissue sections were stained with
antibodies against phospho-Akt (P-Akt), purchased from Cell
Signaling Technology (Beverly, MA). Staining was per-
formed according to the protocol described in the manufac-
turer’s guide. Sections were placed on glass slides and depar-
affinized. The antigen was unmasked by heating samples in
1X Microstain Unmasker Buffer (pH8) (Ventana) for 40
minutes at 98°C. The reaction was quenched using 1%
hydrogen peroxide. Nonspecific binding sites were blocked
with 5% goat serum in phosphate-buffered saline for 1 hour
at room temperature. Samples were then immunostained
using P-Akt (Ser 473) rabbit polyclonal antibody (1:50). The
staining technique used is a two-step method with goat
polyvalent and streptavidin peroxidase reagent (Lab Vision).
Immunohistochemically stained slides were interpreted
blindly and independently by two pathologists (C.L., E.M.),
using a four-tiered grading system based on staining pattern
and intensity. We considered as P-Akt positive all cases with
moderate or strong staining (2 or 3) in at least 10% of
tumor cell nuclei, as previously reported.19
EGFR protein expression was evaluated by immuno-
histochemistry (IHC) using methods and criteria described
elsewhere.13,34 Specimens were stained with monoclonal an-
tibody to EGFR (Zymed Laboratories, Inc., San Francisco,
CA).
EGFR mutation analysis was performed according to
methods previously reported.13
Statistical Analysis
Response to chemotherapy according to EGFR, HER2,
and P-Akt status was assessed by 2 test or Fisher’s exact test.
TTP, overall survival (OS), and the 95% confidence intervals
were evaluated by the Kaplan-Meier method,35 comparing the
groups by log-rank test. Test for proportions was used to
compare RR with chemotherapy and with EGFR-TKIs.
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RESULTS
Patient Characteristics
A total of 190 patients were included in this study.
Patient clinical and biological characteristics are shown in
Tables 1 and 2. Median age was 63.5 years (range, 33–80),
the majority were males (67.4%), and with good performance
status (0–1: 98.4%). Adenocarcinoma was the most frequent
histology (48.9%), followed by squamous cell carcinoma
(25.3%), undifferentiated carcinoma (14.7%), bronchioloal-
veolar carcinoma or adenocarcinoma with bronchioloalveolar
features (10%), and large cell carcinoma (1.1%). The major-
ity of patients were current (37.4%) or former smokers
(46.8%), and standard platinum-based doublets were offered
to 80% of individuals. Thirty-eight patients received single-
agent chemotherapy with gemcitabine or vinorelbine because
of age (27 patients) or the presence of comorbidity contrain-
dicating platinum-based chemotherapy (11 cases). Patients
received standard doses of platinum (cisplatinum 75–80
mg/m2, carboplatin area under the curve 5–6) in combi-
nation with gemcitabine (1000–1250 mg/m2 on days 1 and
8) in 107 cases, in combination with taxanes (paclitaxel
200–225 mg/m2, docetaxel 75 mg/m2) in 23 cases, or in
combination with vinorelbine (25–30 mg/m2 on days 1 and 8)
in 22 cases. Chemotherapy cycles were repeated every 21
days. Patients with locally advanced disease (25.8%) received
sequential radiotherapy and/or surgery with curative intent.
EGFR FISH analysis was successfully performed in
185 cases, and 47 (25.4%) were positive. HER2 was evalu-
ated by FISH in 184 patients, and 53 (28.8%) were positive.
EGFR and P-Akt were successfully evaluated by IHC in 185
and 176 cases, respectively; EGFR was positive in 91 patients
(49.2%), and P-Akt was positive in 82 (46.6%).
Response to Chemotherapy and Biological
Characteristics
In the whole population, RR to chemotherapy was
34.1%. As expected, in patients treated with platinum-based
chemotherapy, RR was 38.9%, higher than in patients treated
with a single agent (13.9%). As summarized in Table 3, RR
was not significantly associated with any biological charac-
teristic. Response to chemotherapy was 37.0% and 32.8% in
EGFR FISH positive and negative, respectively (p 0.6). No
TABLE 1. Clinical and Demographic Characteristics of the
Patient Population
Characteristic No. %
Total patients 190 100
Median age, yr 63.5
Range 33–80
Sex
Male 128 67.4
Female 62 32.6
Stage
III 60 31.6
IV 130 68.4
Histology
Adenocarcinoma 93 48.9
Squamous cell carcinoma 48 25.3
BAC/adeno-BAC 19 10.0
Large cell 2 1.1
Undifferentiated 28 14.7
ECOG performance status
0 156 82.1
1 31 16.3
2 3 1.6
Smoking history
Never 30 15.8
Former 89 46.8
Current 71 37.4
Therapy
Total treated with platinum-based
chemotherapy
152 80.0
Induction platinum-based chemotherapy
followed by RT  surgery
49 25.8
First-line chemotherapy not followed by
any local therapy
103 54.2
Total treated with nonplatinum
compounds
38 20.0
Patients treated with EGFR-TKI therapy as
second or third-line
Total treated 123 64.7
Gefitinib 108 56.8
Erlotinib 15 13.8
BAC, bronchioloalveolar carcinoma; adeno, adenocarcinoma; ECOG, Eastern Co-
operative Oncology Group; RT, radiation therapy; EGFR-TKI, epidermal growth factor
receptor–tyrosine kinase inhibitor.
TABLE 2. Biological Characteristics of NSCLC
Biomarker No. %
EGFR FISH
Total 185 100
Positive 47 25.4
Negative 138 74.6
HER2 FISH
Total 184 100
Positive 53 28.8
Negative 131 71.2
EGFR IHC
Total 185 100
Positive 91 49.2
Negative 94 50.8
P-Akt IHC
Total 176 100
Positive 82 46.6
Negative 94 53.4
EGFR mutation
Total 65 100
Exon 19 15 23.1
Exon 20 2 3.0
Exon 21 7 10.8
Wild type 41 63.1
NCSLC, non-small cell lung cancer; EGFR, epidermal growth factor receptor;
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
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difference in response was also observed between HER2
FISH positive and negative (37.3% versus 32.8%, p  0.5),
between EGFR IHC positive and negative (36.0% versus
33.0%, p  0.6), and between P-Akt positive and negative
(32.1% versus 36.7%, p  0.5). No differences were ob-
served when the analysis was restricted to patients treated
with platinum-based chemotherapy or to individuals receiv-
ing a single-agent treatment.
TTP and Survival
In the study cohort, median TTP was 6.6 months, and
median OS was 20.9 months. These two variables were not
associated with any biological characteristic evaluated in the
present study (Table 4). In patients treated with nonplatinum-
based chemotherapy (n  38), EGFR FISH positive had
longer TTP (8.1 versus 4.1 months, p  0.1) and longer OS
(28.5 versus 14.8 months, p  0.07) than EGFR FISH
negative, although these differences were not statistically
significant. Conversely, HER2 FISH positive had a signifi-
cantly longer TTP (8.4 versus 5.0 months, p  0.01) and OS
(50.8 versus 14.8 months, p  0.01) than HER2 FISH
negative. All patients treated with nonplatinum-based chemo-
therapy had stage IIIB or IV not suitable for local therapy
with curative intent, and 29 patients received a TKI at disease
progression. No different survival results were observed
when patients not treated with a TKI were excluded.
TTP and OS did not differ according to EGFR IHC
status or P-Akt status. In the subgroup of patients treated with
platinum-based chemotherapy (n  152), differences in TTP
and OS were not different irrespective of EGFR (FISH and
IHC), HER2, or P-Akt status.
Because of the possible confounding effects of radio-
therapy or surgery in patients with stage III disease, we
further evaluated TTP and OS in patients who did not receive
subsequent locoregional treatments (stage IIIB with effusion
or stage IV), as illustrated in Table 5. In patients treated with
platinum-based chemotherapy (n  104), TTP and OS were
not different in patients positive or negative for EGFR (FISH
or IHC), HER2, or P-Akt.
EGFR Mutation Analysis
Due to the relevance of EGFR gene mutations for
response to TKI,11–14 we further evaluated the association of
exons 19 through 21 EGFR gene mutations and response to
TABLE 3. Response to Chemotherapy According to the Biological Characteristics
Whole Study Population Platinum-Based Chemotherapy Nonplatinum-Based Chemotherapy
Status Total RR (%) p Total RR (%) p Total RR (%) p
EGFR FISH 46 37.0 0.6 36 38.9 1.0 10 30.0 0.1
EGFR FISH 134 32.8 108 38.9 26 7.7
HER2 FISH 51 37.3 0.5 40 42.5 0.5 11 18.2 0.6
HER2 FISH 128 32.8 104 37.5 24 12.5
EGFR IHC 89 36.0 0.6 70 41.4 0.6 19 15.8 1.0
EGFR IHC 91 33.0 75 37.3 16 12.5
P-Akt IHC 81 32.1 0.5 63 38.1 0.8 18 11.1 0.6
P-Akt- IHC 90 36.7 75 40.0 15 20.0
EGFR mutated 24 29.1 0.6 22 31.8 0.6 2 50.0 NA
EGFR wild type 41 36.5 41 36.5 0 0
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NA, not assessable.
TABLE 4. Time to Disease Progression (TTP) (in Months) and Median Overall Survival (OS) (in Months) According to the
Biological Characteristics
Whole Study Population Platinum-Based Chemotherapy Nonplatinum-Based Chemotherapy
Status Total TTP p OS p Total TTP p OS p Total TTP p OS p
EGFR FISH 46 6.5 0.62 28.0 0.3 36 6.5 0.8 31.1 0.4 10 8.1 0.1 28.5 0.07
EGFR FISH 134 6.4 20.0 108 7.3 20.3 26 4.1 14.8
HER2 FISH 51 6.7 0.91 36.6 0.1 40 6.5 0.2 29.6 0.5 11 8.4 0.02 50.8 0.01
HER2 FISH 128 6.6 18.9 104 7.4 20.3 24 5.0 14.8
EGFR IHC 89 6.5 0.72 26.2 0.3 70 6.6 0.7 31.4 0.1 19 5.0 0.6 28.5 0.3
EGFR IHC 91 7.4 17.9 75 7.6 18.9 16 5.2 21.6
P-Akt IHC 81 6.7 0.27 20.3 0.2 63 6.8 0.4 31.1 0.9 18 5.0 0.4 16.7 0.3
P-Akt IHC 90 6.9 25.3 75 6.9 20.3 15 6.1 21.7
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
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chemotherapy. The analysis was only conducted in a fraction
of patients (65 cases, 34.2%) including 46 cases previously
reported13 because of the scarce amount of tumor tissue
available. Mutations in the EGFR gene were detected in 24
cases, including deletion in exon 19 in 15 cases, point
mutation in exon 20 in two cases, and point mutation in exon
21 in seven cases. All but two patients received a platinum-
based chemotherapy. Response to chemotherapy was
achieved 36.5% in patients with wild-type EGFR and in
29.1% patients with EGFR mutation. Noteworthy, all EGFR
mutation–positive patients responding to chemotherapy had
an exon 19 deletion. Response to chemotherapy was 46.6% in
patients with exon 19 deletion, and 0% in patients with other
EGFR mutations (p  0.02).
Biological Characteristics and Sensitivity to
TKIs
Among the 190 patients analyzed, 123 received a treat-
ment with a TKI as second- or third-line therapy. Gefitinib
was offered in 108 cases, and erlotinib in additional 15
patients. Patients positive for EGFR (FISH, mutation, or
IHC), HER2 FISH, or P-Akt had a significantly higher RR,
TTP, and OS (data not shown). In Table 6, we report the
results in terms of RR and TTP observed according to
different biomarkers in patients treated with chemotherapy
and further treated with a TKI. To avoid any confounding
effect of radiotherapy and/or surgery, TTP analysis was
confined to patients who have not received any locoregional
therapy. RR was higher and TTP was longer for EGFR
FISH– or EGFR mutation–positive patients when treated with
a TKI than with chemotherapy, whereas RR and TTP favored
chemotherapy in EGFR-negative patients. Chemotherapy
produced higher RR and longer TTP than TKIs in patients
negative for HER2 FISH, EGFR IHC, and P-Akt.
DISCUSSION
The aim of this study was to assess whether biological
determinants for TKI sensitivity influenced sensitivity to
first-line chemotherapy in NSCLC, and we observed that the
outcome of patients was not dependent on EGFR, HER2, or
P-Akt status.
During the past 2 years, several retrospective studies
showed that presence of activating EGFR gene mutations and
an increased copy number of the EGFR gene were strongly
associated with TKI sensitivity.11–17 Additional data from
preclinical and clinical experience showed that other biomar-
kers were relevant for TKI sensitivity, including HER218 and
P-Akt.19,20 Recent prospective studies confirmed the central
role of EGFR in TKI sensitivity.21–23 In these trials, patients
with EGFR mutations21–23 or EGFR increased copy number22
treated with a TKI had a higher RR and a longer OS than
reported with standard chemotherapy,3 supporting random-
ized phase III studies comparing chemotherapy with an
EGFR-TKI in selected NSCLC. In designing these trials, it is
critical to know the expected benefit of standard chemother-
apy because it is possible that patients sensitive to TKIs are
the same patients who are also sensitive to chemotherapy. In
a recent retrospective study, Dziadziuszko et al..29 found no
TABLE 5. Time to Disease progression (TTP) and Median
Overall Survival (OS) According to Biological Characteristics
in Stage IIIB and IV Patients Who Received Platinum-based
Chemotherapy
Biomarker Total
TTP
(mo) p
OS
(mo) p
EGFR FISH 29 5.9 0.9 17.4 0.9
EGFR FISH 71 4.8 20.3
HER2 FISH 33 6.2 0.3 25.3 0.1
HER2 FISH 68 5.2 17.9
EGFR IHC 50 5.8 0.8 25.3 0.8
EGFR IHC 50 5.7 17.5
P-Akt IHC 46 6.3 0.7 20.3 0.6
P-Akt IHC 51 4.8 25.3
EGFR mutation  19 5.2 0.4 36.6 0.5
EGFR wild type 28 4.9 20.3
EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization;
IHC, immunohistochemistry.
TABLE 6. Response Rate (RR) and Time to Disease Progression (TTP) According to Different Biomarkers in Patients Treated
with Chemotherapy and Further Treated with a TKI
Biomarker No.
RR to
Chemotherapy (%)
RR to
EGFR-TKIs (%) p No.
TTP with
Chemotherapy (mo)
TTP with
EGFR-TKIs (mo)
EGFR FISH 36 31.4 52.9 0.1 34 6.4 7.1
EGFR FISH- 85 25.9 3.8 0.0002 67 4.1 2.1
HER2 FISH 36 31.4 46.9 0.3 35 5.8 7.4
HER2 FISH 82 25.6 7.7 0.005 64 4.1 2.4
EGFR IHC 60 28.8 31.5 0.9 52 5.2 4.5
EGFR IHC 58 27.6 5.4 0.003 46 4.8 2.1
P-Akt 53 25.0 24.0 1.0 46 5.2 3.6
P-Akt 58 31.0 9.4 0.01 47 4.8 2.1
EGFR mutation 24 30.4 60.9 0.07 21 5.7 9.2
EGFR wild type 41 36.6 2.4 0.001 28 4.9 2.2
For time to disease progression, p value is not assessable. TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; IHC,
immunohistochemistry; RR, response rate.
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difference in TTP or in survival according to EGFR gene
copy number or EGFR expression. In this study, in which the
RR was the primary endpoint, response to chemotherapy was
not different in EGFR-positive and -negative patients, irre-
spective of the method used for EGFR assessment. The
retrospective and noncomparative nature of the present study,
together with the fact that chemotherapy and TKIs were used
sequentially, does not allow us to directly compare chemo-
therapy with EGFR-TKIs. Despite this limitation, we ob-
served that RR was higher and TTP was longer with TKIs
than with chemotherapy in patients with EGFR gene muta-
tions or with EGFR increased gene copy number, suggesting
that EGFR-TKIs could be more effective than chemotherapy
in such patients. Conversely, patient outcome was better with
chemotherapy in EGFR-negative patients, suggesting that, in
absence of the target, a targeted therapy is ineffective and a
less specific treatment, such as chemotherapy, could give
better results. Recently, Lilenbaum et al.36 presented the
results of a phase II randomized study comparing the standard
combination of carboplatin plus paclitaxel versus erlotinib in
untreated NSCLC patients. This study, conducted in uns-
elected NSCLC patients with an Eastern Cooperative Oncol-
ogy Group performance status of 2 showed higher RR and
longer TTP and OS for patients receiving chemotherapy,
supporting the importance of patient selection.
Retrospective analyses of large phase III trials compar-
ing standard chemotherapy and the same chemotherapy reg-
imen plus erlotinib or gefitinib24–27 showed that presence of
EGFR gene mutations was associated with longer survival
independently of the treatment and supporting the hypothesis
that EGFR mutations are positive prognostic factors.37,38
Nevertheless, results of studies on NSCLC patients not ex-
posed to TKI39 and NSCLC patients treated with erlotinib or
gefitinib40–42 have shown that there are differences in patient
outcome based on EGFR genotype. Patients with EGFR exon
19 deletion seems to be more sensitive to TKIs than patients
with other EGFR mutations, including exon 21 mutations.40–42
Although EGFR mutation analysis was not the primary end-
point in our study, which was conducted with a limited
number of patients, it is intriguing that all EGFR mutation–
positive patients responding to chemotherapy had an exon 19
deletion. This aspect has not been previously reported and
should be considered in designing clinical trials, especially in
studies comparing TKIs with chemotherapy.
In this study, the EGFR mutation rate was 34%, higher
than reported in whites.39 Considering the limited number of
patients evaluated for mutations, it is likely that patients
analyzed for EGFR mutations were not representative of the
entire study cohort.
In breast cancer, several studies showed that HER2
amplification was associated with responsiveness to taxane-
and anthracycline-containing regimens.43,44 To the best of our
knowledge, our study provides for the first time evidence that
increased HER2 copy number does not influence chemother-
apy sensitivity in NSCLC. The longer TTP observed in
EGFR-positive or HER2-positive patients treated with single-
agent chemotherapy is surprising and should be investigated
in a larger cohort of patients. Conversely, the survival benefit
observed in this small subgroup of patients is not surprising
considering that the majority of cases received a TKI.
The clinical relevance of Akt activation on chemother-
apy sensitivity in lung cancer has been explored only mar-
ginally. Akt activation has been shown in experimental mod-
els to confer chemoresistance.30 Recently, preclinical data
suggested that Akt confers resistance by modulating the
direct action of p53 on the caspase-dependent mitochondrial
death pathway.45 In our study, no difference in chemotherapy
outcome dependent on Akt status was observed, whereas Akt
phosphorylation resulted in better TKI outcome, as previ-
ously reported.19
The median survival of these patients was longer than
expected considering that the majority of them had stage IV
disease. Although no prognostic factor was taken into ac-
count for patient selection, the high percentage of patients
with good performance status (98.4%) and the effects of
additional therapies (radiotherapy for patients with stage III
disease and second- and third-line systemic treatments for
individuals with stage IV) could have favorably influenced
survival.
In conclusion, these data suggest that EGFR expression
and gene copy number, HER2 gene copy number, and P-Akt
expression are not predictors of response to chemotherapy in
NSCLC. Prospective phase III trials should compare standard
chemotherapy with a TKI in selected NSCLC.
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